Literature DB >> 1672911

AIDS-associated non-Hodgkin lymphoma.

V Beral1, T Peterman, R Berkelman, H Jaffe.   

Abstract

Non-Hodgkin lymphoma is associated with HIV infection. We investigated the epidemiology and aetiology of AIDS-related non-Hodgkin lymphoma by analysing data from cases reported to the Centers for Disease Control, Atlanta, USA, up to June 30, 1989. During this period 97,258 AIDS cases were reported, of whom 2824 (2.9%) had non-Hodgkin lymphoma. The condition was about 60 times more common in AIDS patients than in the general US population. 1686 cases were immunoblastic lymphoma, 548 primary lymphoma of the brain, and 590 Burkitt's lymphoma, a condition which is not normally associated with immunosuppression. The proportion of AIDS patients with immunoblastic lymphoma increased from 0% in those under 1 year old to 3.5% in those aged 50 or more. Primary lymphoma of the brain was constant at 0.6% for all ages. The frequency of Burkitt's lymphoma increased from zero in infants to a peak at 10-19 years of age (1.8%). Each type of lymphoma was twice as common in whites as in blacks and in men as in women. Lymphoma was most common in patients with haemophilia or clotting disorders and least common in those born in the Caribbean or Africa who had acquired HIV by heterosexual contact. Epidemiological data suggested that whilst infectious agents (eg, Epstein-Barr virus) may be associated with development of non-Hodgkin lymphomas in AIDS patients there was probably no single cause for all the types of lymphoma. Perhaps the most puzzling question is why Burkitt's lymphoma is commonly associated with HIV infection but not with other types of immunosuppression.

Entities:  

Mesh:

Year:  1991        PMID: 1672911     DOI: 10.1016/0140-6736(91)92513-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  89 in total

1.  TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues.

Authors:  M Teitell; M A Damore; G G Sulur; D E Turner; M H Stern; J W Said; C T Denny; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

Review 3.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

4.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

5.  Meeting report. Report of meeting of Section of Clinical Immunology and Allergy, 11 March 1991.

Authors: 
Journal:  J R Soc Med       Date:  1992-02       Impact factor: 5.344

6.  Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner.

Authors:  Amy L Ellis; Zhenxun Wang; Xianming Yu; Janet E Mertz
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

7.  Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.

Authors:  Hui-Lee Wong; Elizabeth C Breen; Ruth M Pfeiffer; Brahim Aissani; Jeremy J Martinson; Joseph B Margolick; Richard A Kaslow; Lisa P Jacobson; Richard F Ambinder; Stephen Chanock; Otoniel Martínez-Maza; Charles S Rabkin
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

Review 8.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

9.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

10.  Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.

Authors:  Xianfeng F Zhao; Merry Y Zhao; Ling Chai; Debra Kukuruga; Ming Tan; Sanford A Stass
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.